Thromboaspiration in AMI, without benefit to 30 days.

Original title: Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction. TASTE trial. Reference: Ole Fröbert et al. N Engl J Med 2013. DOI: 10.1056/NEJMoa1308789

One of the biggest challenges of primary angioplasty is to restore normal coronary flow. Thromboaspiration is a relatively simple, quick and cheap it can improve the flow and resolution of ST , however , the above has not been a universal finding in the randomized works , records or meta-analysis published so far. The TASTE ( Thrombus Aspiration in ST – Elevation Myocardial Infarction in Scandinavia ) was a multicenter , randomized , prospective, controlled study designed to evaluate the effect of thromboaspiration on hard clinical end points in patients suffering an ST segment elevation myocardial infarction. The primary end point was death from any cause at 30 days and the secondary endpoints included 30-day rate of re-infarction , stent thrombosis, target lesion revascularization , target lesion revascularization and a composite of death and myocardial re-infarction .

A total of 7244 patients were randomized 1:1 to manual thromboaspiration versus angioplasty alone. At 30 days 2.8% ( 103 of 3621 ) decease of randomized to thromboaspiration versus 3%        (110 of 3623 ) of patients randomized to angioplasty alone ( HR with thromboaspiration, 0.94 CI 95% , 0.72 to 1.22 , P = 0.63 ) . The recurrence rate of re-infarction at 30 days was 0.5 % with thromboaspiration versus 0.9 % with angioplasty alone (HR 0.61 , CI 95 %, 0.34 to 1.07 , P = .09 ).

The rates of stent thrombosis, target vessel revascularization and the injury did not differ significantly between groups. No differences in safety end point as systemic embolism , stroke , perforation or tamponade . The result in the primary end point was consistent across all prespecified subgroups , including those at high risk of thrombosis as those admitted with TIMI 0-1 or those with large amounts of thrombus.

Conclusion: 

Routine aspiration compared with angioplasty alone does not reduce mortality at 30-day in patients suffering  ST segment elevation myocardial infarction.

Editorial Comment:

Since this analysis was limited to a 30-day follow-up clinical differences may not have been observed and that might be apparent with longer follow-up . Indeed the mortality benefit observed in TAPAS study was observed only after a year . The TAPAS also noted a trend toward higher stroke with thromboaspiration ( this complication if it is expected to happen immediately if was related to thromboaspiration) , however this analysis with many more patients than the TAPAS showed no differences. The simple, quick and inexpensive thromboaspiration added to the absence of adverse effects suggests that monitoring would have to wait longer before leaving this practice. 

SOLACI.ORG

More articles by this author

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...